EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)VergleichsstudieMultizentrische Studie

A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52)

Xiaoyong Man, Katya Zaharieva, Grażyna Pulka, Agnieszka Żebrowska, Yunhua Deng, Lally Mekokishvili, Xiaolei Yang, Yunpeng Qi, Cailing Gu, Qingfeng Dong, Min Zheng

Journal of the American Academy of Dermatology · 2025

DOI: 10.1016/j.jaad.2025.08.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Academy of Dermatology, 2025. Verfasst von Xiaoyong Man und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Ustekinumab, Biosimilar Pharmaceuticals, Psoriasis, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: BAT2206 is being developed as a ustekinumab (UST) biosimilar. OBJECTIVES: Equivalent efficacy and comparable safety results of BAT2206 and UST in patients with moderate-to-severe psoriasis up to Week 28 (treatment period [TP] 1) have been reported previously. TP2 (post Week 28 to 52) results are presented here. METHODS: Patients achieving Psoriasis Area and Severity Index response (≥75) at Week 28 entered TP2. Qualified patients of the UST group in TP1 were re-randomized 1:1 into UST-BAT2206 or UST-UST groups, while qualified patients of the BAT2206 group continued with BAT2206 (BAT2206-BAT2206 group). In TP2, secondary efficacy endpoints, pharmacokinetics, safety, and immunogenicity were assessed at Week 32, 40, 44, and 52. RESULTS: A total of 528 patients entered TP2, of which 133, 131, and 264 were assigned to UST-UST, UST-BAT2206, and BAT2206-BAT2206 groups, respectively. The secondary efficacy endpoints and the adverse events showed no obvious differences across all 3 groups. There were no notable differences in the UST serum concentrations. Immunogenicity was comparable, and the switching from UST to BAT2206 did not lead to an increased immunogenicity. LIMITATIONS: No data collected after Week 52. CONCLUSION: Outcomes were comparable among the groups in TP2, with no impact from the UST-to-BAT2206 switch.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabBiosimilar PharmaceuticalsPsoriasisDermatologic AgentsHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultSeverity of Illness IndexTreatment OutcomeAged

Stichwörter der Autor:innen

biosimilarpsoriasisrandomizedtreatment switchingustekinumab

Substanzen

UstekinumabBiosimilar PharmaceuticalsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Diagnostic-Consultative Center XXVIII-Sofia EOOD, Sofia, Bulgaria.
  • Centrum Medyczne Allmed-Badania Kliniczne, Krakow, Poland.
  • Department of Dermatology, NZOZ ALL-MED Centrum Medyczne Specjalistyczne Gabinety Lekarskie, Lodz, Poland.
  • Department of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Petre Shotadze Tbilisi Medical Academy, Tbilisi, Georgia.

Zitieren

APA

Man, X., Zaharieva, K., Pulka, G., Żebrowska, A., Deng, Y., Mekokishvili, L., Yang, X., Qi, Y., Gu, C., Dong, Q., & Zheng, M. (2025). A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52). Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2025.08.005

Vancouver

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, et al. A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52). Journal of the American Academy of Dermatology. 2025. doi:10.1016/j.jaad.2025.08.005

BibTeX
@article{Man2025,
  author = {Man, Xiaoyong and Zaharieva, Katya and Pulka, Grażyna and Żebrowska, Agnieszka and Deng, Yunhua and Mekokishvili, Lally and Yang, Xiaolei and Qi, Yunpeng and Gu, Cailing and Dong, Qingfeng and Zheng, Min},
  title = {A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: Treatment period 2 results (post Week 28 to Week 52)},
  journal = {Journal of the American Academy of Dermatology},
  year = {2025},
  doi = {10.1016/j.jaad.2025.08.005}
}
Kostenlos starten →